Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17839840 | 0.86 | IMPDH2 (0.59) | IMPDH2SMN1; SMN2GAASLC6A4 | |
| SCHEMBL7293153 | 0.81 | IMPDH2 (0.61) | IMPDH2SMN1; SMN2SLC6A4XDH | |
| SCHEMBL10095336 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2GAAXDHNPSR1KRAS | |
| SCHEMBL16455429 | 0.79 | IMPDH2 (0.59) | IMPDH2SMN1; SMN2GAASLC6A4XDH | |
| SCHEMBL22450677 | 0.79 | IMPDH2 (0.59) | IMPDH2SMN1; SMN2GAASLC6A4XDH | |
| SCHEMBL13385265 | 0.79 | IMPDH2 (0.59) | IMPDH2SLC6A4XDHGSK3B | |
| SCHEMBL7273946 | 0.79 | IMPDH2 (0.59) | IMPDH2SLC6A4XDHGSK3BPDK1 | |
| SCHEMBL24853984 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAXDHNPSR1KRAS | |
| SCHEMBL30173392 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAXDHNPSR1KRAS | |
| SCHEMBL30173391 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAXDHNPSR1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841843-A | Compound combined with CRBN protein and degradation agent of CRBN protein | 中国海洋大学 | 2025-04-18 | — | — | CN | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-116917289-A | T-type calcium channel antagonists and uses thereof | 小利兰·斯坦福大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| WO-2022216386-A9 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010051206-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010047982-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | IMPDH2 3604/4885SMN1; SMN2 4020/4885GAA 4132/4885 |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | IMPDH2 4311/4885SMN1; SMN2 3149/4885GAA 4226/4885 |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | IMPDH2 678/4885SMN1; SMN2 4846/4885GAA 553/4885 |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | IMPDH2 678/4885SMN1; SMN2 4846/4885GAA 553/4885 |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | IMPDH2 678/4885SMN1; SMN2 4846/4885GAA 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.